Tumor growth velocity: A modified tumor growth rate defining tumor progression during sorafenib treatment in patients with metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

Tumor growth velocity: A modified tumor growth rate defining tumor progression during sorafenib treatment in patients with metastatic renal cell carcinoma

Published:2018-10-16 Issue:1 Volume:26 Page:75-82
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int. J. Urol.

Author:

Wang Hong-Kai¹²,Xu Wen-Hao¹²,Ma Chun-Guang¹²,Zhou Liang-Ping²³,Shi Guo-Hai¹²,Zhang Hai-Liang¹²,Ye Ding-Wei¹²

Affiliation:

1. Department of Urology; Fudan University Shanghai Cancer Center; Shanghai China

2. Department of Oncology; Shanghai Medical College; Fudan University; Shanghai China

3. Department of Radiology; Fudan University Shanghai Cancer Center; Shanghai China

Funder

National Natural Science Foundation of China

Shanghai Natural Science Foundation of China

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/iju.13807/fullpdf

Reference29 articles.

1. Measuring response in solid tumors: unidimensional versus bidimensional measurement;James;J. Natl Cancer Inst.,1999

2. Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation;Hillman;J. Clin. Oncol.,2009

3. Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST;Nishino;Am. J. Roentgenol.,2012

4. Imaging of lung cancer in the era of molecular medicine;Nishino;Acad. Radiol.,2011

5. Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC);Seidel;Br. J. Cancer,2013

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of first‐line nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma: A multicenter retrospective study;International Journal of Urology;2020-09-06

2. Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study;Clinical Genitourinary Cancer;2019-10

3. C‐reactive protein/albumin ratio is a predictive factor for prognosis in patients with metastatic renal cell carcinoma;International Journal of Urology;2019-07-24